ViiV Healthcare v. Hetero Labs: DOVATO Patent Dispute Ends in Consent Judgment
ViiV Healthcare, Shionogi, and ViiV Healthcare UK sued Indian generic manufacturer Hetero Labs over two patents covering DOVATO, a leading two-drug HIV regimen combining dolutegravir and lamivudine. The Delaware District Court case closed in just 131 days with a negotiated consent judgment that permanently enjoins Hetero from commercialising its ANDA generic product.
ANDA battle over DOVATO ends fast with injunction intact
On 2 August 2024, ViiV Healthcare Company, Shionogi & Co., Ltd., and ViiV Healthcare UK (No. 3) Limited filed an infringement action in the District of Delaware against Hetero USA, Inc. and Hetero Labs Limited, asserting US Patent Nos. 9,242,986 and 11,234,985. The patents cover the dolutegravir and lamivudine combination therapy marketed as DOVATO — a once-daily, two-drug HIV-1 treatment regimen — and the suit was triggered by Hetero’s ANDA filing seeking approval to market a generic version.
The case resolved on 11 December 2024 via a stipulated consent judgment entered by Judge Mitchell S. Goldberg. Under the agreed order, Hetero, its affiliates, successors, and assigns are permanently enjoined from making, selling, importing, or distributing the ANDA product at issue except as specifically authorised by the parties’ confidential Settlement Agreement. All claims and counterclaims were dismissed with prejudice, and neither party was awarded costs or fees.
The 131-day resolution is notably swift for Hatch-Waxman litigation, which typically extends years before trial. The early consent judgment suggests the parties reached a licensing or market-entry date arrangement under the confidential Settlement Agreement — a common mechanism in branded pharmaceutical ANDA disputes. The precise authorised launch date, if any, granted to Hetero remains undisclosed in the public record, leaving the competitive timeline for generic DOVATO entry uncertain.
Filing to Consent Judgment in 131 days
131 days — well below the median ANDA patent trial timeline, consistent with early settlement
Consent judgment and permanent injunction: what the resolution means for both parties
Consent judgment freezes generic entry pending Settlement Agreement terms
A consent judgment is a court-ordered resolution negotiated by both parties and entered by the judge with full legal force. Here, it carries a permanent injunction barring Hetero from commercialising its ANDA dolutegravir/lamivudine product except as specifically authorised by the confidential Settlement Agreement. This is the standard Hatch-Waxman endgame: patent holders obtain injunctive protection while leaving room to grant a licensed entry date in private.
Hatch-Waxman consent judgmentViiV and Shionogi secure injunction protecting DOVATO revenue
ViiV Healthcare and co-plaintiffs Shionogi exit this action with both asserted patents — US9242986 and US11234985 — intact and unchallenged on the merits. The permanent injunction prevents at-risk generic launch by Hetero, protecting DOVATO’s branded market position. The dismissal with prejudice also bars Hetero from reopening these specific claims, though the confidential Settlement Agreement may grant a future authorised entry window.
Patents upheld; injunction securedHetero accepts injunction but likely secures a future licensed launch date
Hetero Labs consents to a permanent injunction on its current ANDA product but almost certainly negotiated a confidential authorised generic entry date as part of the Settlement Agreement — the standard consideration in such arrangements. The dismissal with prejudice forecloses any invalidity or non-infringement arguments Hetero might have raised. Future generic entry, if permitted, will be governed entirely by the private settlement terms, not the public court record.
Injunction accepted; settlement governs entryDOVATO’s two-drug HIV franchise remains shielded — for now
DOVATO is a commercially significant HIV regimen generating substantial revenue for ViiV. The consent judgment, combined with the dual-patent injunction, suggests US market exclusivity is preserved at least through the settlement-authorised period. Other generic filers should note that both US9242986 and US11234985 survived this ANDA challenge without merits adjudication, meaning their validity and scope have not been tested — a factor in any future challenge or FTO analysis.
DOVATO exclusivity preserved near-termFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | ViiV Healthcare, Co. | Company | HIV pharmaceutical innovator — holder of US9242986 and US11234985 (DOVATO)Search in Eureka ↗ |
| Co-Plaintiff | Shionogi & Co., Ltd. | Company | Search in Eureka ↗ |
| Co-Plaintiff | Viiv Healthcare UK (No.3) Limited | Individual | Search in Eureka ↗ |
| Defendant | Hetero USA, Inc. | Company | Indian generic pharmaceutical manufacturer pursuing ANDA approval for dolutegravir/lamivudine tabletsSearch in Eureka ↗ |
| Co-Defendant | Hetero Labs Limited | Individual | Search in Eureka ↗ |
| Co-Defendant | Hetero Labs Limited | Individual | Search in Eureka ↗ |
| Plaintiff counsel | Alexandra M. Joyce | Attorney | Counsel for ViiV Healthcare, Co.Search in Eureka ↗ |
| Plaintiff counsel | Daniel M. Silver | Attorney | Counsel for ViiV Healthcare, Co.Search in Eureka ↗ |
| Plaintiff law firm | McCarter & English LLP | Law Firm | Representing ViiV Healthcare, Co.Search in Eureka ↗ |
| Defendant counsel | Cortlan S. Hitch | Attorney | Counsel for Hetero USA, Inc.Search in Eureka ↗ |
| Defendant counsel | Kenneth Laurence Dorsney | Attorney | Counsel for Hetero USA, Inc.Search in Eureka ↗ |
| Defendant law firm | Morris James LLP | Law Firm | Representing Hetero USA, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Mitchell S. Goldberg | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consent judgment is broad in its injunctive scope — covering not just Hetero USA and Hetero Labs but all affiliates, successors, and assigns — and expressly preserves the court’s jurisdiction to enforce the settlement. Crucially, the injunction is carved out only for activities ‘specifically authorized pursuant to the Settlement Agreement,’ the terms of which are confidential. This language is standard in Hatch-Waxman settlements and is consistent with a negotiated future launch date rather than a permanent bar. No merits ruling was made on validity or infringement of either asserted patent.
US9242986 & US11234985 — dolutegravir/lamivudine HIV combination therapy
US9242986 (application no. US14/272823) and US11234985 (application no. US16/835733) together protect the pharmaceutical composition and therapeutic use of dolutegravir — an integrase strand transfer inhibitor — combined with lamivudine for the treatment of HIV-1. The patents underpin DOVATO, ViiV’s once-daily two-drug regimen approved by the FDA in 2019, and reflect the clinical and formulation innovations that enabled a simplified, nucleotide-sparing HIV treatment approach.
The strategic significance of these patents lies in DOVATO’s position as one of the leading HIV maintenance regimens globally. US11234985’s relatively recent grant (2022) extends the effective patent estate well beyond the older US9242986, creating a staggered exclusivity wall. For any generic manufacturer targeting the dolutegravir/lamivudine market, both patents must be addressed — and this case’s outcome demonstrates that ViiV is prepared to enforce them aggressively and rapidly in Delaware.
Should your team run an FTO against US9242986 and US11234985?
Any pharmaceutical company, CMO, or formulator involved in dolutegravir or lamivudine combination products — whether developing an ANDA, a branded alternative, or a formulation variation — should conduct a freedom-to-operate analysis against both US9242986 and US11234985. The consent judgment in this case confirms ViiV will act swiftly upon ANDA notification, and neither patent’s validity was tested in this proceeding, meaning they carry full presumptive validity.
PatSnap Eureka’s FTO Search Agent can map the full claim scope of both patents against your product specifications, identify prior art that was not cited during prosecution, and surface related family members in other jurisdictions. For HIV combination therapy products, Eureka can also generate a landscape view of ViiV’s and Shionogi’s broader ANDA enforcement history to help your team calibrate risk before filing.
Run a freedom-to-operate analysis on US9242986B2 to assess your product’s exposure
Run FTO in Eureka →Similar HIV combination therapy ANDA patent cases in Delaware
Related Hatch-Waxman infringement cases involving HIV antiretroviral combination therapy patents litigated in Delaware District Court.
What this case signals for the HIV combination therapy IP landscape
Swift consent judgment with injunction is the playbook — but the real terms stay private. Here is what IP teams should take away.
Dual-patent ANDA filings elevate settlement leverage for branded HIV players
ViiV asserted two patents — US9242986 and US11234985 — covering DOVATO. Multi-patent assertions in Hatch-Waxman actions are a well-established strategy: they complicate an ANDA challenger’s invalidity and design-around arguments, increase litigation cost, and typically accelerate settlement. Generic entrants should conduct thorough FTO analysis across the full DOVATO patent estate before filing.
131-day close signals a pre-negotiated settlement framework was likely in place early
Cases that close this quickly in Delaware ANDA litigation are consistent with parties who had commercially aligned interests from early in the dispute. The absence of any cost award and the with-prejudice dismissal suggest a clean, negotiated exit — not capitulation. IP teams monitoring DOVATO’s generic competitive landscape should watch for any FDA tentative approval or authorised generic announcements from Hetero.
ViiV v Hetero — key questions answered
ViiV Healthcare, Shionogi & Co., and ViiV Healthcare UK (No. 3) asserted US Patent Nos. 9,242,986 and 11,234,985 against Hetero USA and Hetero Labs. Both patents cover dolutegravir and lamivudine HIV-1 combination therapy — the active combination in ViiV’s branded product DOVATO.
The case was resolved via a stipulated consent judgment entered on 11 December 2024 by Judge Mitchell S. Goldberg. The judgment permanently enjoins Hetero and its affiliates from making, selling, importing, or distributing its ANDA dolutegravir/lamivudine product except as specifically authorised under the confidential Settlement Agreement. All claims were dismissed with prejudice; no costs or fees were awarded.
The injunction bars Hetero from commercialising its generic DOVATO ANDA product unless expressly permitted by the private Settlement Agreement. This typically means the parties have negotiated a confidential authorised launch date. The precise timing of any authorised generic entry by Hetero is not disclosed in the public court record.
A 131-day closure is notably fast for Delaware Hatch-Waxman litigation, which often runs two or more years before trial. The speed suggests the parties had commercially aligned interests — likely a negotiated launch date and licensing framework — that made extended litigation unattractive. This pattern is consistent with ViiV’s broader enforcement approach in ANDA disputes involving DOVATO.
No merits determination was made. The case settled before any claim construction, validity, or infringement ruling. Both patents were dismissed with prejudice under the consent judgment, meaning their validity and infringement scope remain judicially untested. They retain full presumptive validity for purposes of any future ANDA or enforcement analysis.
PatSnap Eureka searches patents and litigation data to answer instantly.